Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients

1 May 2011

Abstract excerpt

Epidermal growth factor receptor (EGFR) promoter methylation may be responsible for the loss of EGFR expression in neoplastic cells. The primary aim of our study was to verify a possible correlation between EGFR gene promoter methylation and clinical outcome in metastatic colorectal cancer patients receiving chemotherapy with irinotecan and cetuximab. Colorectal samples from patients treated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Treatments and Studies
Share to Epigenetics and DNA Methylation
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21559018
DOI: 10.1038/bjc.2011.161

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patientsPMID 21559018Read ↗

Effect of DNA methylation status on first-line anti-epidermal growth factor receptor treatment in patients with metastatic colorectal cancer.Semantic proximity Read ↗

DNA methylation status as a biomarker of anti‐epidermal growth factor receptor treatment for metastatic colorectal cancerSemantic proximity Read ↗

CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer.Semantic proximity Read ↗

Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.Semantic proximity Read ↗

p16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

Oncosuppressor methylation: a possible key role in colon metastatic progression.Semantic proximity Read ↗

Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report.Semantic proximity Read ↗

Epidermal growth factor receptor in CRC patients in the era of the RAS.Semantic proximity Read ↗

A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.Semantic proximity Read ↗

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.Semantic proximity Read ↗

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.Semantic proximity Read ↗

ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.